Hospice or palliative care denied? We cite 42 CFR §418, the LCD that fits your patient's diagnosis, and ACA §2302 for kids.

Why hospice and palliative denials are uniquely sensitive

A denied hospice election or palliative consult does something other insurance denials do not: it reaches into the final months of a life. The patient and family are already navigating grief, anticipatory loss, and decisions about goals of care. An insurance denial in that context is not just bureaucratic — it can disrupt the only care plan that fits the patient's values.

The good news is that the federal regulations governing hospice are unusually specific and unusually patient-favorable. 42 CFR Part 418 (Hospice Conditions of Participation), the per-diagnosis Local Coverage Determinations (LCDs) published by each Medicare Administrative Contractor (MAC), the ACA §2302 concurrent-care requirement for children, and the National Consensus Project (NCP) Clinical Practice Guidelines for Quality Palliative Care collectively define a coverage standard that most denials do not actually meet. A successful appeal turns the regulation back on the insurer.

This guide walks through the most common hospice and palliative denial categories — eligibility, GIP/CHC level of care, recertification, palliative consults, pediatric concurrent care — and the exact citations that overturn them.

The hospice prognostic standard: 6 months "if disease runs normal course"

The Medicare hospice benefit (42 CFR §418.3) defines terminal illness as "a medical prognosis of 6 months or less if the illness runs its normal course." The phrase "if the illness runs its normal course" is doing a lot of work. It does not require certainty. It does not require that 6-month survival be impossible. It requires a reasonable medical judgment by the certifying physicians that, in the absence of unexpected events, the patient would not survive beyond 6 months.

Two physicians must certify at initial election: the hospice medical director (or hospice physician) AND the attending physician. The hospice physician alone may certify subsequent benefit periods.

Each MAC publishes per-diagnosis Local Coverage Determinations (LCDs) operationalizing the 6-month prognostic standard. The most-cited LCDs:

• Palmetto LCD L34538 — Hospice Determining Terminal Status (covers JM jurisdiction states).
• NGS L33393 — Hospice Determining Terminal Status (covers JK and J6).
• Noridian L33531 — Hospice Determining Terminal Status (covers JE and JF).
• WPS L33393 — Hospice (J5 and J8).
• CGS L33393 — Hospice (JM, J15).
• First Coast L34394 — Hospice (J9 Florida + Caribbean).
• Novitas L34538 — Hospice (JL and JH).

Each LCD contains per-diagnosis decline criteria — for cancer (PPS, weight loss, performance), heart disease (NYHA IV, ejection fraction, frequent hospitalizations), pulmonary disease (FEV1, oxygen dependence, hospitalizations), liver disease (Child-Pugh, INR, ascites, encephalopathy, recurrent variceal bleed), renal failure (declining creatinine clearance, declining urine output, eligibility to discontinue dialysis), dementia (FAST 7+ with comorbid markers), stroke (PPS, dysphagia, weight loss), ALS (rapid progression), and HIV (CD4, opportunistic infections, viral load).

The single most powerful sentence in a hospice eligibility appeal is: "The patient meets the criteria of [LCD number] for [diagnosis] as follows: [point-by-point]."

Hospice eligibility: build the prognostic argument

The successful eligibility appeal contains:

1. Two-physician CTI — Certification of Terminal Illness signed by hospice MD AND attending physician at initial certification (90 days). Specify both NPIs.

2. Per-diagnosis LCD criteria mapped point-by-point — quote the LCD by name and number, then walk through each criterion met.

3. Serial prognostic indicators — PPS / KPS over 3–6 months showing decline; FAST staging for dementia; serial weight loss with percent body weight; serial albumin; ECOG; NYHA class; FEV1; recent hospitalizations and ED visits.

4. Comorbidities supporting prognosis — dementia patients often need FAST 7C+ AND one of six comorbid markers (aspiration pneumonia, recurrent UTI, decubitus stage 2+, fever despite antibiotics, eating disorder, weight loss).

5. The Casarett JAMA 2010 framework — extends the prognostic argument for non-cancer diagnoses where the LCD criteria can feel less concrete.

The Casarett framework asks: would you be surprised if this patient died in the next 6–12 months? Combined with disease-specific decline markers, the answer often establishes terminal status even when no single criterion is determinative.

Hospice recertification: the F2F encounter and the LCD must align

Each Medicare hospice benefit period is structured: two 90-day periods followed by an unlimited number of 60-day periods. Recertification is required at the start of each new period, and beginning with the 3rd benefit period (the first 60-day period), a face-to-face encounter (F2F) by a hospice physician or hospice NP must occur within 30 days prior to the start of that period (42 CFR §418.22(b)(3)).

The F2F encounter must include:

• A clinical narrative describing why the patient continues to meet terminal-illness criteria.
• Reference to the applicable LCD criteria.
• Specific physical-exam, functional, and prognostic findings.
• The clinician's signature, date, and credentials.

Recertification denials almost always allege "patient has stabilized." The counter:

• Submit serial PPS / FAST / weight / albumin / KPS data showing continued decline (small declines count — the LCD does not require rapid deterioration).
• Submit the F2F note with the clinical narrative.
• Quote the applicable LCD and demonstrate ongoing satisfaction of decline criteria.
• Cite §418.21 (benefit periods are unlimited as long as eligibility is maintained) and the CMS Hospice Quality Reporting Program (HQRP) data showing average length of stay by diagnosis — dementia and stroke often exceed 180 days. Long LOS is not disqualifying.

GIP (general inpatient) level of care: document the crisis

Hospice levels of care are defined at 42 CFR §418.302:

• RHC (routine home care) — the default; per-diem rate.
• CHC (continuous home care) — for symptom crisis requiring >=8 hours of predominantly nursing care in a 24-hour period.
• IRC (inpatient respite care) — caregiver respite, max 5 consecutive days, at a Medicare-certified inpatient facility.
• GIP (general inpatient) — for acute symptom crisis that cannot be managed in the home setting — uncontrolled pain, intractable nausea/vomiting, terminal agitation, severe dyspnea, complex wound management, terminal delirium.

GIP denials typically allege "RHC is appropriate." The counter:

• Document the specific symptom crisis with quantitative measures: pain NRS 9–10 with baseline opioid MME and required IV titration; agitation requiring IV midazolam infusion; dyspnea with RR >30 and oxygen requirement >6 L; intractable N&V with refractory antiemetic regimen.
• Document why home setting cannot manage — frequent medication titration, IV access, 24-hr nursing presence, family unable to safely administer.
• Document GIP duration — typical 5–7 days; if longer, document continued crisis.
• Cite §418.302(b)(4) and CMS Manual Chapter 9 §40.2.1.

CHC has a similar argument: document >=8 hours predominantly nursing in 24 hours for symptom crisis, and document home setting attempted and inadequate.

Palliative care consults: distinguish from hospice, cite NCP

Palliative care consults are commonly denied as "duplicative of primary team" or "not separately reimbursable." The distinction between palliative care and hospice matters for the appeal:

• Palliative care is appropriate at any disease stage, concurrent with curative treatment, focused on symptom management, goals-of-care discussion, advance care planning, and care coordination. It is a medical-benefit consult.
• Hospice is for terminal illness with prognosis ≤6 months, with curative treatment for the terminal diagnosis waived under the hospice election (Medicare).

The successful palliative consult appeal:

• Cites the National Consensus Project Clinical Practice Guidelines for Quality Palliative Care (4th ed., 2018) — the foundational document defining palliative care across 8 domains.
• Cites CAPC (Center to Advance Palliative Care) Standards for Palliative Care Programs — operational standards.
• Cites Temel NEJM 2010 — landmark RCT showing early palliative care for metastatic NSCLC improved survival and quality of life. This trial established the medical necessity of palliative care in serious illness.
• Cites AAHPM clinical guidelines for the specific symptom (pain, dyspnea, delirium, nausea).
• Specifies discrete services delivered — pain regimen change with documented MME adjustment, goals-of-care meeting with documented care plan change, completed POLST/ACP forms, family meeting with consensus, psychosocial assessment with referral.

Hospice and Palliative Medicine (HPM) is an ABMS-recognized subspecialty. Boarded physicians (HPM-certified) and nurse practitioners (ACHPN) are the appropriate consultants. AAHPM membership and HPM credentials support appeal weight.

Pediatric concurrent care: ACA §2302 is the trump card

For Medicare adult patients, election of the hospice benefit means waiving curative treatment for the terminal diagnosis (treatments unrelated to the terminal diagnosis remain covered). For children under 21 enrolled in Medicaid or CHIP, this rule does not apply.

The Affordable Care Act §2302 (codified at 42 USC §1396d(o)(1)) requires that children under 21 enrolled in Medicaid or CHIP can receive curative AND hospice services concurrently. This was a landmark expansion at ACA implementation in 2010. Many private insurers have voluntarily followed the concurrent-care model.

The pediatric concurrent-care appeal:

• Cites ACA §2302 by name and the codification (42 USC §1396d(o)(1)).
• Cites CMS Informational Bulletin on Concurrent Care for Children Requirement (issued September 2010 with subsequent updates).
• Cites NHPCO Pediatric Hospice and Palliative Care Standards.
• Documents the curative regimen (oncologic protocol — chemo, RT, surgery, transplant; or other disease-directed therapy).
• Documents the hospice election by parent/guardian with appropriate informed-consent process.
• Cites the AAP Section on Hospice and Palliative Medicine position.

For private commercial plans, even where ACA §2302 may not technically apply, cite the voluntary adoption trend and the AAP position. Many commercial plans now cover concurrent care voluntarily; demand they document the rationale if denying.

Hospice medication coverage: related vs unrelated to terminal diagnosis

Under Medicare hospice (42 CFR §418.202(f)), drugs and biologicals related to the palliation and management of the terminal illness are covered under the hospice benefit. Drugs unrelated to the terminal illness may be covered under Medicare Part D or commercial pharmacy benefit.

Medication denials typically allege "this drug is not on the hospice formulary" or "this drug is unrelated and should be billed elsewhere." The counter:

• For palliation of terminal symptoms — document the symptom and the medication's role in palliation. Most hospice formularies include core palliative agents (opioids, benzodiazepines, anti-emetics, anticholinergics, laxatives, antipsychotics for delirium). Non-formulary requests for palliation should be considered case-by-case.
• For unrelated conditions — bill Part D / commercial. Document the medical-record rationale for "unrelated" determination.
• Cite the hospice IDG plan of care — the IDG (interdisciplinary group) is responsible for the comprehensive plan of care, and medication decisions flow from that plan.

Hospice revocation disputes

The hospice election is controlled by the beneficiary (or representative). The insurer cannot revoke a hospice election. If a denial appears to "revoke" hospice, the cause is usually:

• Eligibility recertification denied — appeal eligibility.
• Insurer applying pre-2024 MA hospice rules — cite CMMI VBID expiration December 31, 2024 and CY2025+ return to Original Medicare hospice carve-out.
• Beneficiary inadvertently signed revocation — re-election is permitted under §418.24(d).

The successful revocation appeal:

• Documents that the beneficiary did not revoke (or revoked and re-elected).
• Cites §418.28 (beneficiary controls election) and §418.24 (election and re-election).
• For MA plans, cites CMS-4201-F.

Medicare Advantage hospice: the VBID expiration and the carve-out return

Medicare Advantage hospice has been complicated. Historically, MA plans did not cover hospice — the hospice benefit was carved out and billed directly to Original Medicare even for MA beneficiaries. From 2021–2024, the CMMI VBID Hospice Benefit Component model brought some MA plans into hospice billing. The VBID model ended December 31, 2024.

For dates of service in 2025 and later, MA hospice has returned to the traditional Original Medicare carve-out. Hospice claims should bill Original Medicare. If an MA plan denies a 2025+ hospice claim, the appeal points to the carve-out return.

For 2021–2024 dates of service, verify whether the specific MA plan was a VBID participant. If yes, the MA plan's coverage rules apply. If no, traditional Medicare carve-out applies regardless.

For any MA hospice or hospice-adjacent denial, cite CMS-4201-F (April 2023, effective January 2024) — MA plans cannot apply more restrictive criteria than Original Medicare.

The peer-to-peer call: prepare for the LCD quote

Hospice and palliative denials almost always qualify for expedited appeal because terminal illness creates risk of harm from delay. Demand expedited review (typically 72 hours).

For peer-to-peer:

• Demand a same-specialty reviewer — HPM-boarded physician or hospice medical director (HMDCB-certified).
• Bring three things: the applicable LCD with criteria mapped point-by-point, the CTI / F2F encounter narrative, and the serial prognostic data.
• Quote 42 CFR §418 by section as needed.

A peer-to-peer with an HPM-boarded reviewer often overturns the denial within minutes when the LCD criteria are clearly mapped.

A note on letter length and tone

A hospice or palliative appeal should be 1.5 to 2 pages:

1. Header — member ID, claim #, service requested, dates of service / benefit period.

2. Diagnosis + ICD-10 + supporting comorbidities (1 paragraph).

3. Two-physician certification + F2F encounter narrative (recert).

4. Prognostic indicators mapped to LCD criteria (concise list).

5. Service rationale — eligibility / level of care / palliative consult / concurrent care.

6. Address denial reason — quote insurer's policy, cite 42 CFR §418, applicable LCD, ACA §2302, AAHPM/NHPCO/CAPC; for MA cite CMS-4201-F.

7. Closing — request expedited overturn; demand peer-to-peer with HPM-boarded reviewer.

Tone is professional, clinically grounded, and patient-family-sensitive. The medical director responds to LCD-mapped clinical documentation. Avoid emotional language but convey clinical context appropriately.

When to escalate

If the first-level appeal fails:

• Original Medicare hospice — Medicare Administrative Contractor (MAC) reconsideration → Qualified Independent Contractor (QIC) → Administrative Law Judge (ALJ) → Medicare Appeals Council → federal court.
• Medicare Advantage (for non-hospice palliative consults or pre-2025 hospice) — Independent Review Entity (IRE / Maximus) → ALJ → Medicare Appeals Council.
• Self-funded ERISA — second-level internal appeal → external review (binding under ACA §2719).
• Fully-insured commercial — state-mandated external review.
• Medicaid managed care (pediatric concurrent care) — state Fair Hearing.

For hospice cases, the QIC and ALJ levels often produce favorable decisions when the documentation is well-structured.

What good looks like

A successful hospice or palliative appeal letter:

• Quotes the applicable per-diagnosis MAC LCD by number (Palmetto L34538, NGS L33393, Noridian L33531, WPS L33393, CGS L33393, First Coast L34394, Novitas L34538).
• Cites 42 CFR §418 by section (§418.3 prognostic standard, §418.21 benefit periods, §418.22 certification, §418.302 levels of care, §418.202 covered services).
• For pediatric cases, cites ACA §2302 (42 USC §1396d(o)(1)).
• For MA cases, cites CMS-4201-F.
• For palliative consults, cites NCP Clinical Practice Guidelines (4th ed., 2018), CAPC Standards, AAHPM, and Temel NEJM 2010.
• Submits two-physician CTI for initial; F2F encounter for 3rd+ benefit period.
• Submits serial prognostic data — PPS/KPS, FAST, weight, albumin, hospitalizations.
• Maps LCD criteria point-by-point to chart documentation.
• Demands expedited peer-to-peer with HPM-boarded reviewer.
• Stays within 2 pages.

Most hospice and palliative denials reverse on first or second appeal when these elements are present. The federal regulations and per-diagnosis LCDs are unusually specific, and the documentation, once structured around them, often carries the appeal mechanically.